Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial
Authors
Keywords
-
Journal
LANCET NEUROLOGY
Volume 21, Issue 1, Pages 31-41
Publisher
Elsevier BV
Online
2021-12-21
DOI
10.1016/s1474-4422(21)00369-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Memantine on QT/QTc Interval in a Healthy Korean Population
- (2021) Jin‐Woo Park et al. Clinical Pharmacology in Drug Development
- Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances
- (2021) Aaron M. Orkin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome
- (2020) Eric D. Hamlett et al. GLIA
- The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer’s Disease Patients and Its Consequence to Oxidative Stress Biomarkers
- (2019) Martin Valis et al. Frontiers in Pharmacology
- Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome
- (2019) Sarah E. Lee et al. TRENDS IN MOLECULAR MEDICINE
- National population‐based estimates for major birth defects, 2010–2014
- (2019) Cara T. Mai et al. Birth Defects Research
- Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome
- (2018) Jonah J. Scott-McKean et al. NEURAL PLASTICITY
- Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis
- (2017) Taro Kishi et al. JOURNAL OF ALZHEIMERS DISEASE
- Predictors of Age of Diagnosis and Survival of Alzheimer’s Disease in Down Syndrome
- (2017) Amanda Sinai et al. JOURNAL OF ALZHEIMERS DISEASE
- Fitting Linear Mixed-Effects Models Usinglme4
- (2015) Douglas Bates et al. Journal of Statistical Software
- The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration
- (2014) Alberto Costa CNS & Neurological Disorders-Drug Targets
- Formoterol, a Long-Acting β2 Adrenergic Agonist, Improves Cognitive Function and Promotes Dendritic Complexity in a Mouse Model of Down Syndrome
- (2013) Van Dang et al. BIOLOGICAL PSYCHIATRY
- Prospects for Improving Brain Function in Individuals with Down Syndrome
- (2013) Alberto C. S. Costa et al. CNS DRUGS
- Pharmacotherapy of Vestibular Disorders and Nystagmus
- (2013) Olympia Kremmyda et al. SEMINARS IN NEUROLOGY
- Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
- (2012) Marisa Hanney et al. LANCET
- Treatment of Alzheimer disease in Down syndrome
- (2012) Alberto C. Costa Nature Reviews Neurology
- Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial
- (2012) R Boada et al. Translational Psychiatry
- Validity of the California Verbal Learning Test–II in Multiple Sclerosis
- (2009) Shane Stegen et al. CLINICAL NEUROPSYCHOLOGIST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search